Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic expanding intracerebral hematoma: A case report.

Radiology case reports·2026
Same author

Risk factors for acute kidney injury after coronary artery bypass graft surgery: a systematic review and meta-analysis.

Frontiers in medicine·2026
Same author

Adaptive Obstacle Avoidance for Robotic Arms Using Hierarchical Reinforcement Learning and Path Optimization.

Annals of the New York Academy of Sciences·2026
Same author

Palladium-Catalyzed Enantioselective Dearomatization of Furan To Access <i>N</i>,<i>O</i>-Spirocycles.

Organic letters·2026
Same author

Controllable deterministic quantum teleportation of multiple sideband qumodes.

Science bulletin·2026
Same author

Catalytic asymmetric reactions of indolylmethanols for the synthesis of chiral indole derivatives.

Chemical communications (Cambridge, England)·2025

Related Experiment Video

Updated: Jul 7, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Potent, selective MCH-1 receptor antagonists.

Shawn D Erickson1, Bruce Banner, Steven Berthel

  • 1Discovery Chemistry, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.

Bioorganic & Medicinal Chemistry Letters
|February 5, 2008
PubMed
Summary

Researchers optimized novel brain-penetrant MCH-1 receptor antagonists for oral bioavailability and selectivity. This work focused on achieving profiles suitable for in vivo efficacy and safety assessments.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Area of Science:

  • Medicinal Chemistry
  • Neuroscience
  • Pharmacology

Background:

  • The Melanin-Concentrating Hormone receptor 1 (MCH-1) is implicated in various physiological processes, including appetite regulation and mood.
  • Developing selective MCH-1 receptor antagonists offers potential therapeutic avenues for neurological and metabolic disorders.

Purpose of the Study:

  • To describe the lead optimization of a novel series of MCH-1 receptor antagonists.
  • To achieve potent, selective, orally bioavailable, and brain-penetrant compounds.
  • To establish a selectivity profile suitable for in vivo efficacy and safety evaluations.

Main Methods:

  • Structure-based drug design and medicinal chemistry optimization strategies.
  • In vitro assays for receptor binding affinity and functional activity.
  • In vitro and in vivo ADME (Absorption, Distribution, Metabolism, and Excretion) profiling.
  • Pharmacokinetic and pharmacodynamic assessments in preclinical models.

Main Results:

  • Identification of a series of potent and selective MCH-1 receptor antagonists.
  • Demonstration of favorable oral bioavailability and brain penetration.
  • Establishment of a robust selectivity profile against related receptors.
  • Compounds exhibited desired pharmacokinetic properties for in vivo studies.

Conclusions:

  • Successful lead optimization yielded promising MCH-1 receptor antagonists with desirable drug-like properties.
  • The developed compounds represent valuable tools for investigating MCH-1 receptor function in vivo.
  • The selectivity profile achieved supports further preclinical development for potential therapeutic applications.